CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim,

DOI: https://doi.org/10.5217/ir.2022.00007

Excel Download

Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients
Pediatric Health, Medicine and Therapeutics. 2012;51   Crossref logo
Link1

Exam 1: Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis and Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
Gastroenterology. 2014;146(1):e14-e15   Crossref logo
Link1 Link2

PGI18 COST-EFFECTIVENESS OF BIOLOGICS FOR MODERATE TO SEVERE ULCERATIVE COLITIS IN BRAZIL
Value in Health. 2020;23:S146   Crossref logo
Link1 Link2

Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics
The Korean Journal of Gastroenterology. 2018;71(4):192   Crossref logo
Link1 Link2 Link3

Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
Alimentary Pharmacology & Therapeutics. 2018;47(4):539-540   Crossref logo
Link1 Link2

Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab
Crohn's Disease and Ulcerative Colitis. 2017;429-433   Crossref logo
Link1

Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis
Journal of Crohn's and Colitis. 2021;15(10):1774-1774   Crossref logo
Link1 Link2 Link3

Sa1029 – Cost-Effectiveness of First-Line Biologics for the Management of Moderate-To-Severe Ulcerative Colitis
Gastroenterology. 2019;156(6):S-260-S-261   Crossref logo
Link1 Link2

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
Therapeutics and Clinical Risk Management. 2013;451   Crossref logo
Link1

A99 COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
Journal of the Canadian Association of Gastroenterology. 2019;2(Supplement_2):197-198   Crossref logo
Link1